Endpoints News Feb 14, 2026 Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more
Endpoints News Feb 13, 2026 Lilly appeals retatrutide classification ruling in case that could impact compounders
Endpoints News Feb 13, 2026 Lundbeck migraine prevention drug succeeds in Phase 2, advancing new therapy class
Endpoints News Feb 13, 2026 Paul Hudson couldn’t quite get Sanofi over the hump; PROTAC developer Arvinas appoints CEO
Endpoints News Feb 13, 2026 PTC Therapeutics withdraws US filing for troubled Duchenne treatment Translarna